Abstract
Twentythree children (♂:12;♀:11) mean age 11 years, with exercise induced asthma participated in a double-blind randomised placebo controlled study. The children received inhaled salmeterol 25 μg; salmeterol 50 μg and placebo by diskhaler at 10 p.m. on three separate days. Next morning (half at 8 a.m. and half at 10 a.m.) they run on a motor-driven treadmill for six minutes with sub-maximal load. Lung function was measured by maximal expiratory flow volume loops before running, immediately after, and 3, 6, 10 and 15 minutes after running. Mean maximum reduction in FEV1 after treadmill run was 34% before inclusion in the study. Mean maximum fall (with 95% C.I.) in FEV1 was significantly greater after placebo: 29.5%(22.9-36.1) than after salmeterol 25 μg: 18.8% (12.2-23.4) or salmeterol 50 μg: 18.4% (12.0-24.8)(p=0.001). In addition to the reduced bronchoconstriction after exercise, baseline lung function (FEV1) before exercise was significantly higher after both salmeterol 25 μg: 2.42 l/s(2.1-2.7) and salmeterol 50 μg: 2.49 l/s(2.2-2.8) than after placebo: 2.19 l/s(1.9-2.5)(p<0.0001). No differences were found between children tested at 8 a.m. or 10 a.m. or between salmeterol 25 μg or 50 μg. Thus inhaled salmeterol 25 μg or 50 μg offered overnight protection against exercise-induced asthma and improved baseline lung function in the morning as compared to placebo.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
